PureTech Health plc (LON:PRTC - Get Free Report) passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of GBX 131.57 ($1.79) and traded as low as GBX 127.40 ($1.73). PureTech Health shares last traded at GBX 127.40 ($1.73), with a volume of 48,707 shares.
PureTech Health Trading Down 0.0%
The stock's fifty day moving average price is GBX 131.57 and its 200 day moving average price is GBX 135.70. The company has a debt-to-equity ratio of 45.82, a current ratio of 3.68 and a quick ratio of 2.51. The stock has a market capitalization of £382.65 million, a P/E ratio of -5.23 and a beta of 1.02.
Insider Activity at PureTech Health
In related news, insider Bharatt Chowrira purchased 167,739 shares of the business's stock in a transaction dated Thursday, July 3rd. The shares were purchased at an average cost of GBX 1 ($0.01) per share, for a total transaction of £1,677.39 ($2,283.10). Insiders own 15.93% of the company's stock.
About PureTech Health
(
Get Free Report)
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider PureTech Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.
While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
